Tebokan Forte 120 mg contains a dry standardized extract of Ginkgo biloba leaves.
Improves memory and circulation. Antidementia drug. Peripheral vasodilator.
120 mg dry quantified extract of Ginkgo biloba leaf (35-67: 1). Extracting agent: acetone 60% (m / m). The extract is quantified against 26.4 ~ 32.4 mg flavonoids, such as flavonoid glucosides and 6.48 – 7.92 mg terpene lactones, of which 3.36 – 4.08 ginkgolides A, B, C and 3.12 – 3.84 mg bilobalide and contains not more than 0.6 μg ginkgolic acid per film-coated tablet.
– Excipients are: croscarmellose sodium; colloidal anhydrous silica; hypromellose; lactose monohydrate; macrogol 1500; magnesium stearate; cornstarch; microcrystalline cellulose; dimethicone – colloidal anhydrous silica – α-octadecyl-ω-hydroxypoly (oxyethylene) -5-sorbic acid – water (anti-foaming emulsion SE 2 dry matter); talc; titanium dioxide E 171; iron oxide E 172.
Adults over the age of 18 take one film-coated tablet twice a day (morning and evening).
Diseases with obstruction of the peripheral arteries, vertigo, tinnitus:
Adults over the age of 18 take one film-coated tablet 1-2 times a day (morning and evening).
Children and adolescents
Tebocan forte 120 mg is not recommended for use in children and adolescents below 18 years due to insufficient data from a study.
Duration of treatment:
The duration of treatment should be at least 8 weeks. If the disease symptoms do not show any improvement or even worsen after a therapeutic period of 3 months, the doctor should assess whether further treatment is justified.
Diseases with obstruction of the peripheral arteries:
Increasing the distance traveled without pain requires a minimum duration of treatment of 6 weeks.
Any additional administration after a period longer than 6-8 weeks does not bring therapeutic benefit.
Ancillary treatment should be given for at least 12 weeks. If there is no therapeutic success after 6 months, no future improvement can be expected after a longer period of treatment.
For the symptomatic treatment of dementia due to organic brain syndrome.